NO942178L - - Google Patents

Info

Publication number
NO942178L
NO942178L NO942178A NO942178A NO942178L NO 942178 L NO942178 L NO 942178L NO 942178 A NO942178 A NO 942178A NO 942178 A NO942178 A NO 942178A NO 942178 L NO942178 L NO 942178L
Authority
NO
Norway
Prior art keywords
group
carbon atoms
production
hydrocarbon radical
hydrogen atom
Prior art date
Application number
NO942178A
Other languages
English (en)
Norwegian (no)
Other versions
NO942178D0 (no
NO305949B1 (no
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO942178L publication Critical patent/NO942178L/no
Publication of NO942178D0 publication Critical patent/NO942178D0/no
Publication of NO305949B1 publication Critical patent/NO305949B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C401/00Irradiation products of cholesterol or its derivatives; Vitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/59Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO942178A 1991-12-13 1994-06-10 20-metylsubstituerte vitamin D-derivater, farmasoeytiske preparater inneholdende disse, og anvendelse derav NO305949B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4141746A DE4141746A1 (de) 1991-12-13 1991-12-13 20-methyl-substituierte vitamin d-derivate
PCT/EP1992/002887 WO1993012081A1 (de) 1991-12-13 1992-12-14 20-methyl-substituierte vitamin d-derivate

Publications (3)

Publication Number Publication Date
NO942178L true NO942178L (fi) 1994-06-10
NO942178D0 NO942178D0 (no) 1994-06-10
NO305949B1 NO305949B1 (no) 1999-08-23

Family

ID=6447341

Family Applications (1)

Application Number Title Priority Date Filing Date
NO942178A NO305949B1 (no) 1991-12-13 1994-06-10 20-metylsubstituerte vitamin D-derivater, farmasoeytiske preparater inneholdende disse, og anvendelse derav

Country Status (24)

Country Link
US (1) US5446035A (fi)
EP (1) EP0637299B1 (fi)
JP (1) JP3280975B2 (fi)
KR (1) KR100271462B1 (fi)
CN (1) CN1035177C (fi)
AT (1) ATE138366T1 (fi)
AU (1) AU670585B2 (fi)
CA (1) CA2125476C (fi)
CZ (1) CZ286579B6 (fi)
DE (2) DE4141746A1 (fi)
DK (1) DK0637299T3 (fi)
ES (1) ES2089585T3 (fi)
FI (1) FI108226B (fi)
GR (1) GR3020097T3 (fi)
HU (1) HUT68263A (fi)
IL (1) IL104074A (fi)
MX (1) MX9207101A (fi)
NO (1) NO305949B1 (fi)
NZ (1) NZ246052A (fi)
PL (1) PL171403B1 (fi)
SK (1) SK280450B6 (fi)
TW (1) TW275060B (fi)
WO (1) WO1993012081A1 (fi)
ZA (1) ZA929650B (fi)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4220757A1 (de) * 1992-06-24 1994-01-05 Schering Ag Derivate in der Vitamin D-Reihe mit Modifikationen in der 20-Position, Verfahren zu ihrer Herstellung, Zwischenprodukte für dieses Verfahren, diese Derivate enthaltende pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln
GB9220272D0 (en) * 1992-09-25 1992-11-11 Leo Pharm Prod Ltd Chemical compounds
IL107185A (en) * 1992-10-06 1998-02-22 Schering Ag History of 52-carboxylic acid, processes for their preparation and pharmaceutical preparations containing them
US6407082B1 (en) * 1996-09-13 2002-06-18 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a vitamin D compound
US20040167106A1 (en) * 1993-06-04 2004-08-26 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of a Vitamin D compound
GB9315253D0 (en) * 1993-07-23 1993-09-08 Res Inst Medicine Chem Chemical compounds
US5428029A (en) * 1993-11-24 1995-06-27 Hoffmann-La Roche Inc. Vitamin D3 fluorinated analogs
US5981597A (en) * 1995-02-13 1999-11-09 Trustees Of The University Of Pennsylvania Differentiating agents for the treatment of inflammatory intestinal diseases
AU2250097A (en) * 1996-02-13 1997-09-02 G.D. Searle & Co. Compositions comprising a cyclooxygenase-2 inhibitor and a leukotriene b4 receptor antagonist
DE19619036A1 (de) 1996-04-30 1997-11-13 Schering Ag Neue Vitamin D-Derivate mit carbo- oder heterocyclischen Substituenten an C-25, Verfahren zu ihrer Herstellung und die Verwendung zur Herstellung von Arzneimitteln
SG70010A1 (en) * 1996-05-23 2000-01-25 Hoffmann La Roche Fluorinated vitamin d3 analogs
US6765002B2 (en) 2000-03-21 2004-07-20 Gustavo Rodriguez Prevention of ovarian cancer by administration of products that induce transforming growth factor-β and/or apoptosis in the ovarian epithelium
US6034074A (en) 1996-09-13 2000-03-07 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a Vitamin D compound
US6028064A (en) 1996-09-13 2000-02-22 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of progestin products
US6511970B1 (en) 1996-09-13 2003-01-28 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of products that induce transforming growth factor-beta and/or apoptosis in the ovarian epithelium
EP1015423B1 (en) 1997-09-08 2003-05-02 F. Hoffmann-La Roche Ag 1,3-dihydroxy-20,20-dialkyl-vitamin d 3? analogs
CA2326117A1 (en) 1998-03-27 1999-10-07 Oregon Health Sciences University Vitamin d and its analogs in the treatment of tumors and other hyperproliferative disorders
US20030188756A1 (en) * 2002-08-19 2003-10-09 Cantorna Margherita T Treatment of inflammatory bowel disease with vitamin d compounds
US6358939B1 (en) 1999-12-21 2002-03-19 Northern Lights Pharmaceuticals, Llc Use of biologically active vitamin D compounds for the prevention and treatment of inflammatory bowel disease
US6989377B2 (en) 1999-12-21 2006-01-24 Wisconsin Alumni Research Foundation Treating vitamin D responsive diseases
US20010044431A1 (en) * 2000-03-21 2001-11-22 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
AU2001278744A1 (en) * 2000-08-17 2002-02-25 Chugai Seiyaku Kabushiki Kaisha Remedial agent for osteoporosis
TWI329105B (en) * 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
CN1849318B (zh) * 2003-07-30 2011-10-12 里格尔药品股份有限公司 用2,4-嘧啶二胺化合物预防和治疗自体免疫疾病的方法
CN101217868A (zh) * 2005-05-10 2008-07-09 德米普瑟尔有限公司 用于皮肤护理的组合物和方法
ZA200710371B (en) 2005-05-10 2009-07-29 Dermipsor Ltd Compositions and methods for treating hyperproliferative epidermal diseases
CA2607901C (en) 2005-06-13 2016-08-16 Rigel Pharmaceuticals, Inc. Methods and compositions for treating degenerative bone disorders using a syk inhibitory 2,4-pyrimidinediamine
PL1734251T3 (pl) * 2005-06-17 2007-05-31 Magneti Marelli Powertrain Spa Wtryskiwacz paliwa
CA2648521A1 (en) * 2006-04-10 2008-02-28 Wisconsin Alumni Research Foundation 1.alpha.-hydroxy-2-(3'-hydroxypropylidene)-19-n0r-vitamin d compounds with a 1,1-dimethylpropyl side chain
US20080051380A1 (en) * 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
US20080051375A1 (en) * 2006-08-25 2008-02-28 Auerbach Alan H Methods for treating cancer comprising the administration of a vitamin d compound and an additional therapeutic agent, and compositions containing the same
CA2838089A1 (en) 2006-08-25 2008-02-28 Cougar Biotechnology, Inc. Methods for treating cancer comprising the administration of a vitamin d compound and an additional therapeutic agent, and compositions containing the same
US20090124587A1 (en) * 2007-07-12 2009-05-14 Auerbach Alan H METHODS FOR TREATING CANCER USING 17alpha-HYDROXYLASE/C17,20-LYASE INHIBITORS
BRPI1007415A2 (pt) 2009-01-27 2016-02-16 Berg Biosystems Llc vitamina d3 e análogos da mesma para aliviar os efeitos colaterais associados com quimioterapia
CA2770683C (en) 2009-08-14 2018-09-04 Berg Biosystems, Llc Vitamin d3 and analogs thereof for treating alopecia
WO2017209934A1 (en) 2016-05-13 2017-12-07 Case Western Reserve University Autophagy activators for treating or preventing skin injury
MX2019001224A (es) 2016-07-29 2019-06-03 Janssen Pharmaceutica Nv Metodos para tratar el cancer de prostata.
US10548908B2 (en) * 2016-09-15 2020-02-04 Nostopharma, LLC Compositions and methods for preventing and treating heterotopic ossification and pathologic calcification
US11903952B2 (en) 2020-05-27 2024-02-20 Northwestern University Vitamin D as an immune modulator to prevent immune-related complication from COVID-19 infection

Also Published As

Publication number Publication date
TW275060B (fi) 1996-05-01
FI942766A0 (fi) 1994-06-10
AU4035693A (en) 1993-07-19
KR940703806A (ko) 1994-12-12
IL104074A0 (en) 1993-05-13
CN1035177C (zh) 1997-06-18
SK280450B6 (sk) 2000-02-14
NO942178D0 (no) 1994-06-10
DE4141746A1 (de) 1993-06-17
NO305949B1 (no) 1999-08-23
AU670585B2 (en) 1996-07-25
ES2089585T3 (es) 1996-10-01
DK0637299T3 (da) 1996-09-30
FI108226B (fi) 2001-12-14
DE59206393D1 (de) 1996-06-27
IL104074A (en) 1998-01-04
KR100271462B1 (ko) 2000-11-15
SK66194A3 (en) 1995-02-08
CN1073677A (zh) 1993-06-30
NZ246052A (en) 1995-07-26
US5446035A (en) 1995-08-29
CA2125476A1 (en) 1993-06-24
ZA929650B (en) 1993-06-09
CZ286579B6 (cs) 2000-05-17
WO1993012081A1 (de) 1993-06-24
EP0637299B1 (de) 1996-05-22
JP3280975B2 (ja) 2002-05-13
HUT68263A (en) 1995-06-28
GR3020097T3 (en) 1996-08-31
CZ141694A3 (en) 1995-01-18
CA2125476C (en) 2003-02-11
JPH07505132A (ja) 1995-06-08
EP0637299A1 (de) 1995-02-08
HU9401456D0 (en) 1994-08-29
PL171403B1 (pl) 1997-04-30
ATE138366T1 (de) 1996-06-15
MX9207101A (es) 1993-08-01
FI942766A (fi) 1994-06-10

Similar Documents

Publication Publication Date Title
TW275060B (fi)
HK116296A (en) Amide derivatives and dermatologic preparations containing the same
DE3664909D1 (en) Vitamin d3 derivatives
ZA858169B (en) New adamantanamine derivatives,processes for their preparation and drugs in which they are present
IL69230A (en) 6,16-dimethyl corticoids,process for the preparation thereof and pharmaceutical compositions containing the same
DE69415812D1 (de) 15,15-dialkylsubstituierte östradiolderivate
IL64614A (en) 6alpha-methylhydrocortisone derivatives,processes for their preparation and pharmaceutical compositions containing them
HUT37935A (en) Process for production of 3-alkoxi-2-n-pirrolidin-n-piridil-n-furil /or n-tienil/-methil-prophil amins
TW252976B (fi)
HUT35658A (en) Process for producing 7-oxo-prostacycline derivatives of selective biological activity
GB1416929A (en) Fluoranthene derivatives
ES8200703A1 (es) Procedimiento para la preparacion de 1-hidroxi-esteroides
SI0746556T1 (en) Tricyclic compounds having affinity for the 5-ht1a receptor
ES2085544T3 (es) Procedimiento para la fabricacion de 8-n,n-dialquilaminotriciclo-(5.2.1.02,6)decano.
ES2059702T3 (es) Politioureas, procedimiento para su fabricacion y empleo de estas politioureas para evitar o reducir la formacion de costras en reactores.